News
Vertex seeks to mobilise Sh5 billion for the Bond Fund through the issuance of 50 million units, and a further Sh5 billion ...
Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes – Vertex to initiate a Phase 1/2 ...
Pharma Vertex, CRISPR's gene-editing therapy Casgevy wins early FDA nod to treat beta thalassemia By Kevin Dunleavy Jan 16, 2024 3:40pm CRISPR Vertex Pharmaceuticals FDA Casgevy (exa-cel) ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today provided updates on its Phase 1/2 clinical trial of VX-880, an investigational stem cell-deri ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results